AstraZeneca trumpets the 'momentous' data they found for Tagrisso in an adjuvant setting for NSCLC — but many of the experts aren’t cheering along
AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.
Cancer R&D chief Jos …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
